Moderna Stock Analysis

The AI-based fundamental analysis of Moderna’s stock provides a comprehensive assessment of its performance and potential risks.

Positive Fundamentals:

1. Superior risk-adjusted returns: Moderna has demonstrated strong performance compared to its sector peers over the past 12 months, achieving superior risk-adjusted returns, which indicates that it has managed risks effectively and outperformed its peers.
2. Superior return on assets (ROA): The management of Moderna has delivered better returns on its assets compared to its peers in the most recent four quarters, positioning it in the top quartile. This suggests efficient asset utilization and effective management.
3. High market capitalization: Moderna is among the largest entities in its sector, indicating stability and market leadership. High market capitalization can also reflect investor confidence and liquidity.
4. Superior revenue growth: Moderna has exhibited top quartile revenue growth over the previous five years compared to its sector peers. This indicates strong demand for its products and services and a potentially promising outlook for future revenue growth.
5. Superior return on equity (ROE): Moderna’s management has achieved better returns on equity compared to its peers in the most recent four quarters, placing it in the top quartile. This reflects efficient use of shareholders’ equity to generate profits.

Negative Fundamentals:

1. Overpriced compared to book value: Moderna’s stock is trading at a high price compared to its peers’ median on a price-to-book value basis. This suggests that the stock may be overvalued relative to its underlying assets.
2. Overpriced compared to earnings: Moderna’s stock is trading at a high price compared to its peers on a price-to-earnings basis, exceeding the sector median. This indicates that investors may be paying a premium for each dollar of earnings generated by the company.
3. High volatility: Moderna’s total returns have been volatile over the past five years, exceeding the median for its sector. Investors should assess their risk tolerance before investing in such a volatile stock.
4. Negative cash flow: Moderna experienced negative total cash flow in the most recent four quarters, which could indicate challenges in generating sufficient cash to cover operating expenses and investments.
5. Negative free cash flow: Similarly, Moderna had negative total free cash flow in the most recent four quarters, indicating that it may be burning through cash to finance its operations and growth initiatives.
6. Low earnings growth: Moderna has demonstrated below-median earnings growth over the previous five years compared to its sector peers. This suggests that the company may face challenges in increasing profitability and earnings over time.

MRNA Stock Forecast

1. Average Analyst Target Price: Based on the forecasts of 8 analysts, the average target price for Moderna Inc’s stock over the next 12 months is USD 122.27. This target price represents the consensus among analysts regarding the expected future value of the stock.
2. Average Analyst Rating: The average analyst rating for Moderna Inc is “Buy,” indicating a positive sentiment among analysts regarding the stock’s potential. This rating reflects the collective opinion of analysts on the outlook for the company’s performance and future prospects.
3. Stock Target Advisor’s Analysis: Stock Target Advisor’s own analysis of Moderna Inc’s stock is “Neutral.” This assessment is based on a combination of 5 positive signals and 6 negative signals identified by the AI algorithm. It suggests a balanced perspective on the stock’s performance, considering both favorable and unfavorable indicators.
4. Current Stock Price: At the last closing, Moderna Inc’s stock price was USD 105.09. This figure represents the price at which the stock was traded on the most recent trading day and serves as a reference point for investors evaluating the stock’s performance.
5. Price Movement: Over the past week, Moderna Inc’s stock price has changed by -0.48%, indicating a slight decline in value during this period. However, over the past month, the stock has experienced a positive movement of +2.00%. Despite this short-term gain, the stock has seen a significant decline of -33.60% over the last year, reflecting fluctuations in market conditions and investor sentiment over a longer timeframe.

STA Research

STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.